Some PAH patients on sotatercept can stop taking prostacyclin analogues

In a small study of 34 pulmonary arterial hypertension (PAH) patients taking triple therapy plus sotatercept, some were able to stop taking selexipag or treprostinil. The study didn't have a set protocol but considered each patient's situation individually.

Those whose PAH worsened when their prostacyclin analogue doses decreased or stopped regained their health once the dose was restarted. Those who were able to stop their prostacyclin analogue did not have their PAH worsen over the study follow-up period, which lasted at least 14 months. There were no specific characteristics showing which patients would or would not be able to stop prostacyclin therapies, and the long-term effects of stopping them is still unknown, so much more research needs to be done.

Read the European Respiratory Journal article. The paper is still in press, but the link will redirect to the final published version once it is available.